wwwext.amgen.comOCT 12 min read$AMGN

AMGEN ISSUES INAUGURAL GREEN BOND TO ADVANCE ESG GOALS| Amgen

Amgen (AMGN) issued its first $750 million green bond, part of a $4 billion senior notes offering, to fund environmental projects. The bond has a 3.000% coupon and matures in 2029. Proceeds will support Amgen's ESG goals, including carbon neutrality by 2027. S&P Global Ratings endorsed the green framework.

Original reporting

wwwext.amgen.com

Published Oct 1, 2026, 12:30 PM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Oct 1, 2026, 12:30 PM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

AMGEN ISSUES INAUGURAL GREEN BOND TO ADVANCE ESG GOALS| Amgen — source image — Source · wwwext.amgen.com

Decision brief

The 30-second read

$AMGNNeutralMed

Why it matters

The issuance signals Amgen's commitment to sustainability and may attract ESG‑focused capital, while modestly increasing its debt load.

Market read

First‑time green bond issuance by a major biotech could set a precedent for ESG financing in the sector.

What to watch

Potential tax benefits and lower cost of capital for green‑linked projects could improve long‑term cash flow.

Relevance 1/10Novelty 8/10Timing: today

Background

Amgen, a leading biotech firm and Dow Jones component, is expanding its ESG financing toolkit with a $750 M green bond.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$AMGNNeutralHigh confidence

Context

Amgen announced the issuance of a $750 million green bond, its first such financing, advancing its ESG goals.

Expected impact

possible modest pressure as the market prices in the added debt, offset by ESG demand support

Evidence & confidence

Large, first‑time green bond issuance is a material financing event; impact on share price will depend on investor appetite for ESG debt versus leverage concerns.

Market effects

Sector

Highlights growing ESG financing trend in biotech and broader healthcare sector.

Regional

May boost interest in US ESG bond market, influencing regional investors seeking green assets.

Global

Adds to global green bond supply, signaling biotech firms' commitment to sustainability.

Counterpoint

What could challenge this read

Some investors may view the added debt as a risk, questioning whether ESG branding outweighs leverage increase.

Key entities

company
Amgen
US‑listed biotech company (NASDAQ:AMGN) issuing its inaugural green bond.
rating_agency
S&P Global Ratings
Provided second‑party opinion confirming alignment with Green Bond Principles.

Read at source ← All news

OCT 1

$AMGNMedAI 9/10

Imdelltra extends survival in relapsed small cell lung cancer, Korean investigator says

Amgen's Imdelltra (tarlatamab) showed extended survival in relapsed small cell lung cancer. In the DeLLphi-304 trial, median overall survival was 13.6 months with tarlatamab vs. 8.3 months with chemotherapy. Professor Ahn Myung-ju of Hanyang University Medical Center presented the findings at an Amgen Korea press conference.

koreabiomed.com2 min

SEP 30

$AMGNMedAI 8/10

Is Amgen (AMGN) Undervalued Following Its Phase 3 Sjögren's Disease Trial Update?

Amgen (AMGN) reported positive Phase 3 trial data for its Sjögren's disease drug, dazodalibep, boosting its autoimmune pipeline. The stock has surged 17.2% in 90 days and 29.3% year-to-date. Analysts debate its valuation, with one model suggesting it's overvalued at $423.64 vs. a fair value of $359.98, while another DCF model estimates it's undervalued at $672.77.

simplywall.st3 min

SEP 30

$AMGNMedAI 9/10

Amgen reveals 6-point drop in lupus severity behind phase 2 win for Horizon antibody

Amgen's phase 2 trial of daxdilimab showed a 6-point reduction in lupus severity at the lower dose, meeting primary and secondary endpoints. The study involved 72 patients with discoid lupus. Amgen plans to advance daxdilimab into registrational development, acquired from Horizon Therapeutics in 2023. The drug previously failed in systemic lupus trials.

fiercebiotech.com2 min

SEP 29

$AMGNHighAI 9/10

Amgen (AMGN) Has a New Growth Opportunity. But How Much Is It Really Worth?

Amgen (AMGN) reported positive Phase 3 trial results for dazodalibep in systemic Sjögren’s disease, meeting primary endpoints. Citi reaffirmed a Neutral rating and $405 price target, citing unanswered questions about efficacy and competitive profile. Amgen's Q2 2026 revenue grew 10% YoY to $10.1B, with key growth drivers like TEZSPIRE and UPLIZNA. However, legacy products faced biosimilar erosion, with Prolia and XGEVA sales declining 32% and 34%, respectively.

insidermonkey.com2 min

SEP 29

$AMGNLowAI 9/10

Amgen (AMGN), What Is Behind The Fresh Attention?

Amgen (AMGN) reported positive Phase 3 trial data for dazodalibep in Sjögren's disease, boosting its autoimmune pipeline. Shares rose 15.5% in 90 days and 27.6% year-to-date. Analysts debate valuation, with some arguing it's 16.2% overvalued at $418.13, while others see potential in future cash flows. Legacy drug erosion and competitive pressures are key risks.

finance.yahoo.com3 min

SEP 27